Hopewell Therapeutics and Foxcroft Therapeutics partner to advance cancer vaccines using tissue-targeting lipid nanoparticles, enabling improved delivery systems with large-animal trials planned later in 2026.
Hopewell Therapeutics | 09/03/2026 | By News Bureau | 179
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy